secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001493152-25-021555
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q3 revenue $71.6M (+45% YoY), net income $1.0M; VEVYE revenue $22.6M (+22% QoQ)
--------------------------------------------------------------------------------

- Total revenue $71.6M (+45% YoY); GAAP net income $1.0M vs loss $4.2M YoY; Adj. EBITDA $22.7M vs $8.8M
- VEVYE revenue $22.6M (+22% QoQ); national DED market share 10.5% (up 2.7pp); coverage agreements with largest PBM effective Jan 2026
- IHEEZO revenue $21.9M (+70% YoY); on track to exceed $50M annual revenue by year-end 2025
- Agreed to acquire Melt Pharmaceuticals (MELT-300) for non-opioid sedation; refinancing cut interest ~$3M/yr, added $50M liquidity

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225021555/0001493152-25-021555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225021555/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer